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Type 1 diabetes (T1D) is an autoimmune disease leading
to b-cell destruction. MicroRNAs (miRNAs) are small non-
coding RNAs that control gene expression and organ for-
mation. They participate in the pathogenesis of several
autoimmune diseases, but the nature of miRNAs contrib-
uting to b-cell death in T1D and their target genes remain
to be clariﬁed. We performed anmiRNA expression proﬁle
on human islet preparations exposed to the cytokines
IL-1b plus IFN-g. Conﬁrmation of miRNA and target gene
modiﬁcation in human b-cells was performed by real-time
quantitative PCR. Single-stranded miRNAs inhibitors were
used to block selected endogenous miRNAs. Cell death
was measured by Hoechst/propidium iodide staining and
activation of caspase-3. Fifty-seven miRNAs were de-
tected as modulated by cytokines. Three of them, namely
miR-23a-3p, miR-23b-3p, andmiR-149-5p, were downreg-
ulated by cytokines and selected for further studies.
These miRNAs were found to regulate the expression of
the proapoptotic Bcl-2 proteins DP5 and PUMA and con-
sequent human b-cell apoptosis. These results identify a
novel cross talk between a key family of miRNAs and
proapoptotic Bcl-2 proteins in human pancreatic b-cells,
broadening our understanding of cytokine-induced b-cell
apoptosis in early T1D.
Type 1 diabetes (T1D) is a multifactorial autoimmune disease
characterized by selective pancreatic b-cell destruction in the
course of islet inﬂammation (insulitis), which is triggered
by a complex dialogue between the immune system and the
target b-cells (1). Many of the key steps of this dialog are
regulated by candidate genes for T1D (2–4), in cross talk
with environmental cues such as viral infections (5–7).
The inﬂammatory process is mediated by T cells (mostly
CD8+ and, to a lesser extent, CD4+ lymphocytes) and mac-
rophages (8–10). These invading immune cells contribute
to selective b-cells destruction via both cell-to-cell contact
and through the local release of proinﬂammatory cytokines
such as IL-1b, IFN-g, tumor necrosis factor-a (TNF-a), and
IL-17A (1,11,12).
MicroRNAs (miRNAs) are a family of endogenous small
noncoding RNAs with;22 nucleotides in length. They bind
to the 39 untranslated region (UTR) of target genes and
inhibit gene expression by degrading and/or preventing
translation of their target messenger RNAs (13). miRNAs
play a crucial role in organ formation during embryogenesis,
including pancreas development and b-cell differentiation
(14). Moreover, they display an important role in maintain-
ing functional b-cell mass (15–17) and endocrine cell iden-
tity (18,19) during adult life.
Several recent studies have indicated a role for
miRNAs in the regulation of autoimmunity progres-
sion and diabetes development (20–23), including the regu-
lation of inﬂammatory cytokine-mediated b-cell dysfunction
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and death (24–26). Additionally, there may be a link
between miRNAs and regulation of T1D candidate genes
(27) and b-cell responses to viral infection (28). The
ultimate mechanisms by which these miRNAs and their
target genes regulate human b-cell dysfunction and death
remain, however, to be clariﬁed. Particularly, it remains
unclear whether miRNAs, individually or as families, regu-
late the activity of the proapoptotic Bcl-2 family mem-
bers that execute pancreatic b-cell death (1,7). Against this
background, we presently aimed to identify novel cytokine-
modulated miRNAs in human pancreatic islets and, departing
from these ﬁndings, to elucidate the proapoptotic pathways
regulated by these miRNAs in the human b-cells. Our ﬁnd-
ings identiﬁed a novel family of miRNAs that regulate two
key proteins involved in human b-cell apoptosis, namely DP5
and PUMA.
RESEARCH DESIGN AND METHODS
Culture of Human Islet Cells and the Human b-Cell
Line EndoC-bH1
Human islets from 13 donors without diabetes were
isolated in Pisa using collagenase digestion and density
gradient puriﬁcation (29). The donors (seven men and
six women) were 71 6 3 years old and had a BMI of
256 1 kg/m2 (Supplementary Table 1). Islet b-cell percentual
content, as evaluated by immunoﬂuorescence for insulin
using a speciﬁc anti-insulin antibody (Supplementary Table
2) was 54 6 3%. The islets were cultured at 6.1 mmol/L
glucose as previously described (2,30). The human b-cell line
EndoC-bH1 (provided by Dr. R. Scharfmann, University of
Paris, Paris, France) (31) was cultured as previously de-
scribed (12,32).
Cell Treatment
Both human islet cells and the EndoC-bH1 cells were
exposed to the following cytokine concentrations, based
on previous dose-response experiments performed by our
group (30,32,33): recombinant human IL-1b (R&D Sys-
tems, Abingdon, U.K.), 50 U/mL; and recombinant human
IFN-g (PeproTech, London, U.K.), 1,000 U/mL.
TaqMan miRNA Array Proﬁling
Total RNA was isolated with the miRNeasy micro kit
(Qiagen, Venlo, the Netherlands). DNase digestion was per-
formed using RNase-Free DNase kit (Qiagen) following the
manufacturer’s instructions. The quality of the extracted
RNA was evaluated using a Bio Drop instrument (Isogen
Life Science, Temse, Belgium). miRNA expression proﬁling
was performed using TaqMan Array Human MicroRNA
Cards Panel A v2.1 (Life Technologies, Paisley, U.K.), which
allowed us to evaluate the expression of 384 miRNAs.
miRNAs were reverse-transcribed using Megaplex RT pri-
mers Human Pool A v2.1 (Thermo Fisher Scientiﬁc). A
total of 500 ng RNA was used for each reaction, which
included 1.33 mL of 103 Megaplex RT primers, 0.33 mL of
100 mmol/L deoxynucleotide nucleoside triphosphate,
1.33 mL of 103 RT buffer, 1.50 mL of 25 mmol MgCl2,
0.17 mL of 20 U/mL RNAse Inhibitor, 2.50 mL of 50 U/mL
Multiscribe Reverse Transcriptase, and 0.33 mL H2O (all
from Life Technologies). The product of this reaction was
then incubated for 40 cycles at 16°C for 2 min, 42°C for
1 min, 50°C for 1 s, and then at 85°C for 5 min. Then, 9 mL
synthesized cDNA was loaded in TaqMan Array Human
MicroRNA Cards following the manufacturer’s instructions
(Life Technologies). A ViiA7 Real Time PCR instrument
(Applied Biosystems-Life Technologies) was used to perform
TaqMan Array Human MicroRNA Cards reaction runs.
RNA Interference
The short interfering RNAs (siRNAs) and single-stranded
miRNA inhibitors used in this study are described in Sup-
plementary Table 3. The siRNAs targeting DP5 and PUMA
have been previously validated, including comparison
against a second siRNA causing similar biological effects
(34). The optimal concentration of siRNAs used for cell
transfections (30 nmol/L) was previously established
by our group (30,35). Single-stranded miRCURY LNA in-
hibitors (Exiqon, Vedbaek, Denmark) that speciﬁcally
block endogenous miRNAs were used at a concentration
of 120 nmol/L based our own dose-response experiments
(data not shown) and as described (25). Allstar Negative
Control siRNA (siCTRL; Qiagen) was used as negative con-
trol in all experiments. This siCTRL does not affect b-cell
gene expression or insulin release as compared with non-
transfected cells (35). Transient transfection was performed
with Lipofectamine RNAiMAX lipid reagent (Invitrogen-Life
Technologies) following the manufacturer’s instruction.
After an 8-h transfection, cells were cultured for a 48-h
recovery period before exposure to cytokines.
Assessment of Cell Viability
The percentage of viable, apoptotic, and necrotic cells
was determined by staining with the DNA-binding dyes
propidium iodide (5 mg/mL; Sigma-Aldrich, Bornem, Bel-
gium) and Hoechst dye 33342 (5 mg/mL; Sigma-Aldrich)
as described (30,36). A minimum of 600 cells were
counted for each experimental condition by two inde-
pendent observers, with one of them unaware of sample
identity. The agreement between ﬁndings obtained by
the two observers was always .90%. In some cases, apo-
ptosis was also conﬁrmed by caspase-3 cleavage by Western
blot (see below).
Measurement of miRNA and mRNA Expression
A total of 40 and 150 ng total RNA was reverse-transcribed
for miRNA and mRNA detection, respectively. cDNA was
generated with the miScript II RT Kit (Qiagen) following
the manufacturer’s instruction for miRNA detection or
as previously described (9) for mRNA expression. A total
of 1 ng cDNA was used as a template for Real-Time PCR
reaction using the miScript SYBR Green PCR kit and ap-
propriate miScript Primer Assay for individual miRNAs of
interest (Qiagen), following the manufacturer’s instruc-
tions. A Rotor-Gene Q (Qiagen) was used for both human
islets and human EndoC-bH1 cell samples. All samples
were run in duplicate, and miRNA expression was nor-
malized to the expression level of two small nucleolar
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RNAs (RNU6 and SNORD61) or miR-375-3p (an islet-
speciﬁc miRNA for which expression is not modiﬁed by
cytokine treatment; see RESULTS below). miRNA expres-
sion was determined using relative quantiﬁcation (RQ)
method (RQ = 22DCt). A total of 15 ng cDNA was used as
a template for real-time PCR for mRNA ampliﬁcation
using iQ SYBR Green Supermix on a LightCycler instru-
ment (Roche-Diagnostic, Vilvoorde, Belgium) and on a
Rotor-Gene Q (Qiagen), respectively, for human islets
and human EndoC-bH1 cells. The concentration of the
gene of interest was calculated as copies per microliter
using the standard curve method (37), and gene expres-
sion values were corrected by the housekeeping gene
b-actin, for which expression in human islets is not af-
fected by cytokine treatment (30,38). The primers used
in this study are provided in Supplementary Table 4.
Western Blot
For Western blot, cells were washed with cold PBS and
lysed using Laemmli sample buffer. Total proteins were
extracted and resolved by 8–14% SDS-PAGE, trans-
ferred to a nitrocellulose membrane, and immunoblotted
with the speciﬁc antibodies for the protein of interest
(Supplementary Table 1) as described (30). The densito-
metric values were normalized by the housekeeping pro-
teins b-actin or a-tubulin.
Immunoﬂuorescence
Double immunoﬂuorescence for insulin and cleaved
caspase-3 was performed on human dispersed islets
after miR-23a-3p inhibition and cytokine treatment as
previously described (39).
Luciferase Assay
HeLa cells were transfected with dual luciferase reporter
plasmids pEZXMT04-DP5–39 UTR (HmiT088427-MT06)
together with a precursor expressing vector pEZX-miR-23a
(HmiR0298MR04; Genecopoeia, Rockville, MD). pEZX-miR
scramble vector (CmiR-0001-MR04) was used as control.
A total of 125 ng total DNA was transfected at a ratio of
1:50 (39 UTR/miRNA). HeLa cells were harvested 48 h
posttransfection and assayed using Dual Luciferase Re-
porter assay (Promega, Fitchburg, WI). Luciferase activ-
ity was measured using a GLOMAX 20/20 luminometer
(Promega).
Ethics Statement
Human islet collection and handling were approved by the
local ethics committee in Pisa, Italy.
Statistical Analysis
Data are presented as mean values 6 SEM or plotted as
box plots, indicating lower quartile, median, and higher
quartile, with whiskers representing the range of the
remaining data points when the number of experiments
is $4 for each conditions. Alternatively, when the num-
ber of experiments is ,4, data are represented as points
indicating individual experiments. Comparisons were per-
formed by two-tailed paired Student t test or ANOVA fol-
lowed by paired Student t test with Bonferroni correction,
as indicated. A P value ,0.05 was considered as statisti-
cally signiﬁcant.
RESULTS
Cytokine Treatment Modiﬁes miRNA Expression in
Human b-Cells
To identify relevant miRNAs involved in cytokine-induced
b-cell apoptosis and dysfunction, three independent human
islets preparations were left untreated or treated for 48 h in
the presence of proinﬂammatory cytokines IL-1b plus IFN-g.
A global miRNA expression proﬁle was determined by
TaqMan Human MicroRNA Array Cards (Fig. 1A). Data
were exported using VIIA7 RUO software and then analyzed
using Expression Suite software v1.0.3 (Life Technologies).
Only miRNAs with a Ct ,35, in which the Ct is the thresh-
old cycle to detect ﬂuorescence for speciﬁc miRNAs, and a
high efﬁciency ampliﬁcation plot were taken into consider-
ation for subsequent analysis. A total of 231 of 384 miRNAs
analyzed were considered as present in our samples. All raw
data were normalized using three small nucleolar RNAs in-
cluded in the card (RNU6, RNU44, and RNU48). Twenty-two
miRNAs were found upregulated in cytokine-exposed human
islets (considering a cutoff value of fold change $2 versus
untreated islets), whereas 35 miRNAs were found downregu-
lated after cytokine treatment (considering a cutoff value of
fold change #0.75 versus untreated islets) (Supplementary
Table 5). Comparison of this list of cytokine-modulated
miRNAs against available data on miRNA expression proﬁle
performed in puriﬁed human a and b-cells (19) indicates
that 12 modiﬁed miRNAs, namely miR-101-5p, miR-129-
5p, miR-145-5p, miR-149-5p, miR-154-5p, miR-193b-3p,
miR-23b-3p, miR-27a-3p, miR-27b-3p, miR-361-5p, miR-
494-5p, and miR-654-3p, are enriched in b-cells, whereas
3 modiﬁed miRNAs, namely miR-146a-5p, miR-221-3p,
and miR-708-5p, are more expressed in a cells. Using the
miRWalk database (40) and the miRecords target prediction
program (41) and based on the available literature (42), we
initially selected for subsequent studies on two miRNAs,
namely miR-23a-3p and miR-23b-3p, targeting key genes
potentially involved in b-cell death. Cytokine-induced down-
regulation of miR-23a-3p and miR-23b-3p was conﬁrmed in
the same set of samples by real-time quantitative PCR
(qPCR), using custom-designed primers (Fig. 1B and C).
Moreover, downregulation of additional miRNAs poten-
tially involved in cell death (i.e., miR-149-5p, miR-221-
3p, and miR-27a-3p) was also evaluated (Supplementary
Fig. 1B–D). Of note, there was no modiﬁcation in the
expression of miR-375-3p, a well-established islet-speciﬁc
miRNA involved in pancreas development and mainte-
nance of b-cell identity (17) (Supplementary Fig. 1A),
whereas miR-146a-5p and miR-155-5p (Supplementary
Fig. 1E and F), two well-established proinﬂammatory
miRNAs (24,43), were upregulated. Similar results were
observed in additional human islet preparations (inde-
pendent experiments from the array screening) (Supple-
mentary Fig. 2) and insulin-producing human EndoC-bH1
cells (Supplementary Fig. 3). There were, however, some
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differences between human islets and human EndoC-
bH1 cells regarding miRNA modulation. Speciﬁcally,
the observed downregulation of miR-27a-3p in human
islets (Supplementary Figs. 1D and 2D) was not con-
ﬁrmed in EndoC-bH1 cells (Supplementary Fig. 3D),
and there was a very low expression (Ct .35 or unde-
tectable) of miR-155-5p in EndoC-bH1 cells. These small
differences observed between human islets and human
EndoC-bH1 cells may be due at least in part to the cell
heterogeneity within the pancreatic islet. Thus, compar-
ison between the miRNA expression proﬁles of whole
human islets against the FACS-enriched b-cell popula-
tion (44) indicates a higher miR-27a-3p and miR-155-
5p expression in human islets as compared with enriched
b-cells (44), whereas there is a good similarity for most of
the other miRNAs.
miR-23a-3p and miR-23b-3p Regulate the Expression of
Proapoptotic Bcl-2 Family Members in Human b-Cells
We next investigated whether predicted target genes
involved in b-cell death were regulated by cytokine
treatment, in an opposite direction as compared with
miR-23a-3p and miR-23b-3p. The Ct values of expression
of miR-23 family members under basal condition in hu-
man islets and human EndoC-bH1 cells were, respec-
tively, 18.3 6 0.1 and 24.1 6 0.1 for miR-23a-3p and
18.3 6 0.1 and 19 6 0.1 for miR-23b-3p (n = 7). A de-
crease in miR-23a-3p and miR-23b-3p expression in hu-
man islets (Fig. 2A and B) and human EndoC-bH1 cells
(Fig. 3A and B) was paralleled by increased mRNA expres-
sion of PUMA and NOXA (Fig. 2D and E) in human islets
and DP5, PUMA, NOXA, BAX, BIM-total, and BIM-small
(Fig. 3C–H) in human EndoC-bH1 cells. These results
support the hypothesis that proapoptotic Bcl-2 family
members are regulated, directly or indirectly, by miR-
23a-3p and miR-23b-3p in b-cells.
To elucidate the molecular mechanisms by which miR-
23a-3p and miR-23b-3p regulate b-cell survival, single-
stranded miRNAs inhibitors were used to block these
endogenous miRNAs. An 80 and 60% decrease of miR-
23a-3p expression was, respectively, observed in human
Figure 1—miRNA proﬁle of human islets exposed or not to proinﬂammatory cytokines. Human islets (A–C) were left untreated or treated
with IL-1b plus IFN-g for 48 h. miRNAs were then isolated, and miRNA expression proﬁling was performed using TaqMan Array Human
MicroRNA Cards Panel A v2.1 as described in RESEARCH DESIGN AND METHODS. A: Dendrogram of the global miRNA expression proﬁle.
Columns correspond to individual samples exposed or not to cytokines, whereas rows correspond to the individual miRNAs analyzed.
The scale color from blue to red corresponds to the abundance of miRNA expression reported as normalized delta cycle threshold
(dCT; blue: dCT value, 22.18; red: dCT value, 18). All raw data were normalized using three small nucleolar RNAs included in the card
(RNU6, RNU44, and RNU48). Expression of miR-23a (B) and miR-23b (C ) was assayed in the same samples by RT-PCR and normalized
by two different small nucleolar RNAs (RNU6 and RND61). The results are from three independent human islet preparations (A–C ).
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islets and in human EndoC-bH1 cells (Fig. 4A and C) using
an miR-23a-3p inhibitor, followed or not by cytokine ex-
posure. A .90% decrease of miR-23b-3p expression was
observed in human EndoC-bH1 cells using an miR-23b-3p
inhibitor in both untreated and IL-1b plus IFN-g–treated
cells (Fig. 4D). Because of the close similarity between
miR-23a-3p and miR-23b-3p, we observed an important
cross-reaction between the inhibitors, which decreased
expression of both miRNAs in parallel in human EndoC-
bH1 cells (Fig. 4C and D). Thus, ﬁndings with the indi-
vidual inhibitors should be interpreted as mediated by
inhibition of both miR-23a-3p and miR-23b-3p.
The miR-23a-3p inhibitor exacerbated basal apoptosis,
as evaluated by nuclear dyes, in both human islets and
human EndoC-bH1 cells (Fig. 4B and E and Supplemen-
tary Fig. 4A and B, respectively). A similar increase in
apoptosis was observed using the miR-23b-3p inhibitor
in human EndoC-bH1 cells (Fig. 4E and Supplementary
Fig. 4A and B). Cytokine-induced apoptosis was also
augmented in both human islets and human EndoC-
bH1 cells using miR-23a-3p inhibitor (Fig. 4B and E
and Supplementary Fig. 4A and B) and in EndoC-bH1
cells after exposure to the miR-23b-3p inhibitor (Fig. 4E
and Supplementary Fig. 4A and B). In line with these
Figure 2—Cytokines coregulate the expression of miR-23a-3p, miR-23b-3p, NOXA, and PUMA in human pancreatic islets. Human islets
were left untreated or treated with IL-1b plus IFN-g for 48 h. Expression of miR-23a-3p (A) and miR-23b-3p (B) was assayed by RT-PCR
and normalized by two different small nucleolar RNAs (RNU6 and RND61). Expression of DP5 (C ), PUMA (D), NOXA (E), BAX (F ), BIM-total
(G), and BIM-small (BIMs; H) was assayed by RT-PCR and normalized by the housekeeping gene b-actin. Results are represented as box
plots, indicating lower quartile, median, and higher quartile, with whiskers representing the range of the remaining data points (A–H). *P <
0.05, **P < 0.01 vs. untreated cells, paired Student t test. Data are shown as mean 6 SEM of four to seven independent experiments.
104 MicroRNAs Regulate Human b-Cell Apoptosis Diabetes Volume 66, January 2017
observations, the inhibitors for miR-23a-3p and miR-23b-
3p increased expression of cleaved caspase-3 in human
EndoC-bH1 cells (Fig. 4F and G), conﬁrming apoptosis
activation. Similar ﬁndings were observed by double immu-
noﬂuorescence for insulin and cleaved caspase-3 in human
islets after use of the miR-23a-3p inhibitor (Fig. 5), indi-
cating that at least part of the observed cell death in hu-
man islet cells takes place at the b-cell level, which is in line
with the observed increase in cell death in the human b-cell
line EndoC-bH1 cells (Fig. 4E and Supplementary Fig. 4).
Exposure of cells to the miR-23a-3p inhibitor increased
mRNA expression of the proapoptotic Bcl-2 family mem-
bers DP5, PUMA, BAX, and BIM (Fig. 6A, B, D, and E,
respectively), whereas inhibition of miR-23b-3p increased
expression of DP5 and PUMA (Fig. 6A and B) in human
EndoC-bH1 cells following or not exposure to IL-1b plus
IFN-g. No increase in NOXA was observed after inhibition
of miR-23a-3p or miR-23b-3p (Fig. 6C). A mild increase of
protein expression of DP5 and PUMA was observed after
the use of miR-23a-3p and miR-23b-3p inhibitors in hu-
man EndoC-bH1 cells (Supplementary Fig. 5A, B, C, and D,
respectively), whereas no modiﬁcation in BAX and BIM
protein expression after miR-23 family inhibition was
detected (data not shown). In contrast, there was no
change in expression of the antiapoptotic Bcl-2 family
members Mcl-1 and BCL-XL or in APAf-1 after the use of
Figure 3—Cytokines coregulate miR-23a-3p, miR-23b-3p, and proapoptotic Bcl-2 family members in human EndoC-bH1 cells. Human
EndoC-bH1 cells were left untreated or treated with IL-1b plus IFN-g for 48 h. Expression of miR-23a-3p (A) and miR-23b-3p (B) was
assayed by RT-PCR and normalized by two different small nucleolar RNAs (RNU6 and RND61). Expression of DP5 (C ), PUMA (D), NOXA
(E ), BAX (F), BIM-total (G), and BIM-small (BIMs; H) was assayed by RT-PCR and normalized by the housekeeping gene b-actin. Results are
represented as box plots, indicating lower quartile, median, and higher quartile, with whiskers representing the range of the remaining data
points (A–H). *P < 0.05, **P < 0.01, ***P < 0.001 vs. untreated cells; paired Student t test. Data are shown as mean 6 SEM of seven
independent experiments.
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Figure 4—Inhibition of miR-23a-3p and miR-23b-3p exacerbates apoptosis in human islets and human EndoC-bH1 cells. Dispersed
human islets (A and B) and human EndoC-bH1 cells (C–G) were transfected with siCTRL or anti–miRNAs targeting miR-23a-3p (human
islets and EndoC-bH1 cells) or miR-23b-3p (EndoC-bH1 cells) for 8 h. After a 48-h recovery, cells were left untreated or treated with IL-1b
plus IFN-g for 48 h as indicated. Expression of miR-23a-3p (A and C ) and miR-23b-3p (D) was assayed by RT-PCR and normalized by
two different small nucleolar RNAs (RNU6 and RND61) (A) or by miR-375-3p expression (C and D). Apoptosis was evaluated by Hoechst/
propidium iodide staining after 48 h of cytokine treatment (B and E ). Cleaved caspase-3 and b-actin protein expression were evaluated by
Western blot after 48 h of cytokine treatment; one representative blot of ﬁve independent experiments is shown (F ). The optical density
quantiﬁcation of cleaved caspase-3 (as shown in F) was corrected by b-actin expression (G). Results are represented as box plots,
indicating lower quartile, median, and higher quartile, with whiskers representing the range of the remaining data points (A–E ). In G,
results were normalized against the highest value in each independent experiment, considered as 1. *P < 0.05, **P < 0.01, ***P < 0.001
vs. siCTRL untreated cells; §P < 0.05, §§§P < 0.001, #P < 0.05, ##P < 0.01 as indicated by bars; ANOVA followed by paired Student
t test with Bonferroni correction. Data are shown as mean 6 SEM of ﬁve to seven independent experiments.
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miR-23a-3p or miR-23b-3p inhibitors in human EndoC-
bH1 cells following or not exposure to IL-1b plus IFN-g
(data not shown). Taken together, these results suggest
that miR-23a-3p and miR-23b-3p regulate b-cells apoptosis
by modulating expression of key proapoptotic Bcl-2 protein
family members.
To evaluate if DP5 is a direct target of miR-23a-3p,
HeLa cells were transfected with a luciferase construct
containing the 39 UTR sequence of DP5 (Supplementary
Fig. 6A). miR-23a-3p did not decrease the luciferase activ-
ity in cells transfected with the construct containing 39
UTR of DP5, suggesting an indirect effect of miR-23a-3p
on DP5 modulation. We next evaluated whether depletion
of the miR-23 family upregulated expression of c-JUN, a
key regulator of DP5 expression in b-cells (45). Inhibition
of miR-23a-3p and miR-23b-3p increased by .16-fold
c-JUN mRNA expression in human EndoC-bH1 cells un-
der basal condition or following exposure to IL-1b plus
IFN-g (Fig. 6F). Interestingly, analysis on whether miR-23
family members target negative regulators of c-JUN
mRNA expression, identiﬁed ARNT, HDAC4, MEF2C,
NCOA2, TNFAIP3, ZNF382, and ZNF384 as predicted
targets of miR-23 family.
Knockdown of PUMA or DP5 Protects Human
EndoC-bH1 Cells From Cytokine-Induced Apoptosis
in the Context of miR-23a-3p Inhibition
To determine whether the observed effects of miR-23a-3p
on proapoptotic Bcl-2 proteins is causally related to b-cell
death, we next knocked down PUMA or DP5 in combina-
tion with the miR-23a-3p inhibitor. This abrogated miR-
23a-3p inhibitor–dependent induction of PUMA and DP5
(Fig. 7A and B, respectively) in both untreated and cytokine-
treated human EndoC-bH1 cells; the inhibition of miR-
23a-3p was conﬁrmed by real-time qPCR (Fig. 7C and D).
Importantly, blocking PUMA and DP5 induction in parallel
to miR-23a-3p inhibition also prevented the increase in
Figure 5—Inhibition of miR-23a-3p augments cleaved caspase-3 expression in human b-cells. Human dispersed islets were transfected
with siCTRL (A–D and I–L) or an anti-miRNA targeting miR-23a-3p (E–H andM–P) for 8 h. After a 48-h recovery, cells were left untreated (A–H)
or treated with IL-1b plus IFN-g (I–P) for 48 h. After cytokine treatment, cells were ﬁxed and used for histological studies. Fluorescent
microscopy analysis of insulin (A, E, I, and M in green) and cleaved caspase-3 (F, J, and N in red) shows the presence of double-positive
cells for insulin and cleaved caspase-3 (H, L, and P, merged in yellow). Hoechst staining (C, G, K, and O in blue) shows the presence of
nuclear condensation in the apoptotic cleaved caspase-3–positive cells (G, K, and O, arrows). Double-positive cells for insulin and cleaved
caspase-3 are indicated by the arrows (E, F, H–J, L–N, and P).
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apoptosis secondary to depletion of this miRNA (Fig. 7E
and F), indicating that upregulation of these two BH3-
only proteins is part of the mechanisms by which a
cytokine-induced miR-23a-3p decrease contributes to
apoptosis of human pancreatic b-cells. This, and the
above-described activation of caspase-3, indicates that
miR-23a-3p regulates the intrinsic or mitochondrial apo-
ptotic pathway in human b-cells.
To investigate whether additional miRNAs contribute
to cytokine-induced apoptosis mediated by Bcl-2 family
members, we studied miR-149-5p, another miRNA observed
as downregulated by cytokines in our initial screening
(Supplementary Fig. 1B and Supplementary Table 5).
miRNA target prediction programs indicated miR-149-
5p as a possible modulator of the Bcl-2 family members
PUMA and BIM. Using an miR-149-5p inhibitor, there
was a 60–80% decrease of miR-149-5p expression in hu-
man EndoC-bH1 cells exposed or not to cytokines (Supple-
mentary Fig. 7A). miR-149-5p depletion in both untreated
and cytokine-treated human EndoC-bH1 cells increased
apoptosis, as evaluated by nuclear dyes (Supplementary
Fig. 7B). Furthermore, miR-149-5p inhibition led to upreg-
ulation of DP5, PUMA, and BAX (Supplementary Fig. 7C,
D, and F) and a mild modulation of BIM (Supplementary
Figure 6—Inhibition of miR-23a-3p and miR-23b-3p increases expression of proapoptotic Bcl-2 family members in human EndoC-bH1
cells. EndoC-bH1 cells were transfected with siCTRL or with anti-miRNAs targeting miR-23a-3p and miR-23b-3p for 8 h. After a 48-h
recovery, cells were left untreated or treated with IL-1b plus IFN-g for 48 h as indicated. Expression of DP5 (A), PUMA (B), NOXA (C),
BAX (D), BIM (E), and c-JUN (F). Results are represented as box plots, indicating lower quartile, median, and higher quartile, with whiskers
representing the range of the remaining data points (A–F). *P< 0.05, **P< 0.01, ***P< 0.001 vs. siCTRL untreated cells; §P< 0.05, §§P< 0.01,
§§§P< 0.001, #P< 0.05, ##P< 0.01, ###P< 0.001 as indicated by bars; ANOVA followed by paired Student t test with Bonferroni correction.
Data are shown as mean 6 SEM of six to seven independent experiments.
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Fig. 7G), whereas no modiﬁcation in Mcl-1 and BCL-XL was
observed (data not shown). This supports the concept that
individual genes can be regulated by different miRNAs and
that several miRNAs can participate in the regulation of key
genes (13), such as the ones involved in b-cell death. We
next knocked down PUMA or DP5 in combination with the
miR-149-5p inhibitor. This abrogated miR-149-5p inhibitor–
dependent induction of PUMA and DP5 (Supplementary
Fig. 8A and B, respectively) in both untreated and cytokine-
treated human EndoC-bH1 cells; the inhibition of miR-
149-5p was conﬁrmed by real-time qPCR (Supplementary
Fig. 8C and D). Importantly, blocking PUMA and DP5
Figure 7—Knockdown (KD) of PUMA or DP5 protects human EndoC-bH1 cells against cytokine-induced apoptosis in the context of miR-
23a-3p inhibition. EndoC-bH1 cells were transfected with siCTRL, siPUMA, or anti–miR-23a-3p or cotransfected with siPUMA plus anti–
miR-23a-3p (A, C, and E) for 8 h. After a 48-h recovery, cells were left untreated or treated with IL-1b plus IFN-g for 48 h as indicated. The
KD of PUMA (A) was conﬁrmed by RT-PCR and normalized by the housekeeping gene b-actin. Expression of miR-23a-3p (C ) was assayed
by RT-PCR and normalized by miR-375-3p expression. Apoptosis was evaluated by propidium iodide/Hoechst staining after 48 h of
cytokine treatment (E). EndoC-bH1 cells were transfected with siCTRL, siDP5, or anti–miR-23a-3p or cotransfected with siDP5 plus anti–
miR-23a-3p (B, D, and F ) for 8 h. After a 48-h recovery, cells were left untreated or treated with IL-1b plus IFN-g for 48 h as indicated. The
KD of DP5 (B) was conﬁrmed by RT-PCR and normalized by the housekeeping gene b-actin. Expression of miR-23a-3p (D) was assayed by
RT-PCR and normalized by miR-375-3p expression. Apoptosis was evaluated by propidium iodide/Hoechst staining after 48 h of cytokine
treatment (F ). Results (A and B) were normalized against the highest value in each independent experiment, considered as 1. *P < 0.05,
**P < 0.01, ***P < 0.001 vs. siCTRL untreated cells; §P < 0.05, §§P < 0.01, §§§P < 0.001 vs. siCTRL cytokine-treated cells; #P < 0.05,
##P < 0.01, ###P < 0.001, @@@P < 0.001 as indicated by bars; ANOVA followed by paired Student t test with Bonferroni correction. Data
are shown as mean 6 SEM of ﬁve independent experiments.
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induction in parallel to miR-149-5p inhibition also pre-
vented the increase in apoptosis secondary to depletion of
this miRNA (Supplementary Fig. 8E and F), as we pre-
viously observed for miR-23a-3p (Fig. 7E and F).
DISCUSSION
A signiﬁcant reduction of functional b-cell mass because
of increased b-cell death is the key feature of T1D. During
the early stages of the disease, pancreatic islets are ex-
posed to proinﬂammatory mediators released by the in-
vading immune cells. Available information, mostly from
animal models and in vitro experiments, suggests that
this results into changes in the expression of key b-cell
gene networks involved in b-cell function and phenotype,
induction of endoplasmic reticulum (ER) stress, and in-
ﬂammation (1,46,47). Locally produced proinﬂammatory
mediators recruit further immune cells that enhance
release of chemokines and cytokines, leading to ampliﬁ-
cation of the inﬂammatory process. Prolonged cytokine
exposure and the consequent persistent ER stress, possi-
bly in combination with environmental factors such as
viral infections, may activate downstream pathways
such as JNK phosphorylation and the transcription fac-
tors nuclear factor-kB and STAT1, eventually triggering
expression of proapoptotic Bcl-2 proteins, cleavage, and
activation of caspases and cell death (1,7,48). The ﬁne
regulation of this process, particularly in human b-cells,
remains to be clariﬁed.
The Bcl-2 family members can be subdivided into three
different groups: antiapoptotic (i.e., Bcl-2, Bcl-XL, Mcl-1,
and A1), proapoptotic (i.e., BAX, BAK, and BOK) Bcl-2
proteins, and proapoptotic BH3-only proteins (48). Addi-
tionally, the BH3-only proteins can be divided into two
subgroups: the sensitizers (i.e., DP5, BAD, and NOXA)
and the activators (i.e., BID, BIM, and PUMA) of apopto-
sis (48,49). It has been previously shown that PUMA and
DP5, two of the most important regulators of the intrin-
sic apoptotic pathway, are induced in b-cells by exposure
to the cytokines IL-1b plus IFN-g or to chemical ER stres-
sors, leading to BAX translocation to the mitochondria,
caspase-3 activation, and b-cell death (45,50).
miRNAs are key regulators of gene expression, and
some have been shown to sensitize b-cells to cytokine-
induced apoptosis (24,25). Thus, prolonged exposure of
mouse islets to IL-1b or to TNF-a results in upregulation
of miR-146a-5p, miR-34a-5p, and miR-21-5p (24). Fur-
thermore, cytokine-induced upregulation of miR-101a-
3p and miR-30b-5p decreases expression of antiapoptotic
Bcl-2 proteins in the mouse insulin- producing cell line
MIN6 (26), whereas suppression of Bcl-2 upon miR-34a-
5p induction contributes to palmitate-induced apoptosis
in MIN6 cells (51). In line with these observations, cyto-
kines upregulate miR-29-5p, which exacerbates cytokine-
induced apoptosis via inhibition of the antiapoptotic Bcl-2
protein Mcl-1 (25). In contrast, the possible contribution
of miRNAs to the cytokine-induced upregulation of pro-
apoptotic BH3-only proteins in b-cells remains to be clariﬁed.
Against this background, we presently performed a global
miRNA expression proﬁle on three independent human
islets preparations treated or not with the cytokines
IL-1b plus IFN-g. Twenty-two and 35 miRNAs were found
up- and downregulated, respectively, in human islets after
IL-1b plus IFN-g treatment. Of particular interest, these
cytokines induced a signiﬁcant downregulation of miR-23a-
3p, miR-23b-3p, and miR-27a-3p, all belonging to the same
miRNA family. miR-23b-3p is also downregulated in islets
from 4- and 8-week NOD mice (25). Downregulation of
miR-23a-3p and miR-27a-3p in posttraumatic brain in-
jury contributes to neuronal cell death by directly upreg-
ulating the proapoptotic Bcl-2 family members BAX,
NOXA, and PUMA (42), suggesting that this may be an
important mechanism by which cytokines upregulate
these key proapoptotic Bcl-2 family members. To test this
hypothesis, miR-23a-3p and miR-23b-3p were inhibited in
Figure 8—Proposed model for the cytokine-induced cross talk be-
tween miRNAs and proapoptotic Bcl-2 proteins in b-cells. The
proinﬂammatory cytokines IL-1b plus IFN-g downregulate expres-
sion of miR-23a-3p, miR-23b-3p, and miR-149-5p in b-cells. De-
creased expression of these inhibitory miRNAs leads to increased
mRNA expression of key proapoptotic Bcl-2 proteins. Speciﬁcally,
miR-23a-3p and miR-23b-3p modulate the BH3-only sensitizer DP5
(at least in part via upregulation of c-JUN) and the BH3-only acti-
vator PUMA, whereas miR-23a-3p regulates both the BH3-only
sensitizer BIM and the proapoptotic Bcl-2 protein BAX. Additionally,
inhibition of miR-149-5p expressions results in increased mRNA
expression of both DP5 and PUMA. This complex interaction be-
tween miRNAs, transcription factors, and downstream proapoptotic
proteins leads to cleavage and activation of caspase-3 and, sub-
sequently, to b-cell apoptosis.
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human b-cells. Because miR-23a-3p and miR-23b-3p are
very similar and differ by only one nucleotide in their
39 ends, which is less important for miRNA action than
the 59 end, the inhibitors of miR-23a-3p and miR-23b-3p
used led to inhibition of both miRNAs. Thus, all data
obtained based on these inhibitors should be interpreted
as indicating broad effects of the miR-23 family. miR-23
inhibition increased apoptosis under both basal condition
and following cytokine treatment. This was paralleled by
upregulation of several BH3-only proteins, with the most
consistent ﬁndings observed for DP5 and PUMA. Impor-
tantly, knocking down PUMA or DP5 reverted the proapop-
totic effects of miR-23a-3p inhibition, suggesting that these
two BH3-only proteins are regulated in an indirect way
by proinﬂammatory cytokines (i.e., via the inhibition of
miRNAs of the miR-23 family). Using HeLa cells, we did
not observe a direct interaction between the miR-23 family
and DP5 (for technical reasons, these experiments could
not be performed in human EndoC-bH1 cells). This sug-
gests the possibility of an indirect effect of these miRNAs
on DP5 via upregulation of c-JUN (current study), a tran-
scription factor previously shown by us to regulate DP5
expression (45). It remains to be determined how miR-23
cross talk with PUMA. Of note, the results described above
show additive effects of PUMA/DP5 and miR-23 in that
they both affect apoptosis, and the BH3-only proteins
seem to be regulated downstream of the miRNAs. It re-
mains to be proven, however, that these signals interact
and the ultimate mechanisms involved. The current study
should therefore be interpreted with caution.
The fact that these novel observations were obtained
in human islets and in a human b-cell line increases their
potential relevance to human T1D. Additional miRNAs
targeting Bcl-2 family members, such as miR-221-3p
and miR-149-5p, were also found downregulated in our
screening, suggesting a more complex cross talk between
miRNAs and proapoptotic Bcl-2 family members in
b-cells. In line with this, inhibition of miR-149-5p also
led to upregulation of DP5, PUMA, and BAX. An overview
of this complex cross talk is provided in Fig. 8.
In conclusion, the results of this study identify a
potential novel cross talk between a family of miRNAs
and key proapoptotic Bcl-2 proteins in human pancreatic
b-cells, providing a new mechanistic understanding of in-
ﬂammation-induced b-cell apoptosis.
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